Onesource Specialty Pharma Limited has received a regulatory disclosure from Pronomz Ventures LLP regarding the acquisition of additional equity shares. The disclosure, made under Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, details a strategic increase in shareholding by the promoter group entity.

Transaction Details

Pronomz Ventures LLP acquired 33,906 equity shares of Onesource Specialty Pharma Limited through open market purchases on January 30, 2026. The acquisition represents 0.03% of the company's total share capital.

Shareholding Pattern Changes

The acquisition resulted in a marginal increase in the promoter group's collective shareholding. Before the transaction, Pronomz Ventures LLP and its persons acting in concert held 3,45,71,199 shares, representing 30.17% of the total voting capital.

Promoter Group Structure

The disclosure identifies Pronomz Ventures LLP as the acquirer, with several entities and individuals classified as persons acting in concert. The group includes:

• Karuna Business Solutions LLP
• Tenshi Pharmaceuticals Private Limited
• Arco Lab Private Limited
• Arun Kumar Pillai
• Vineetha Mohanakumar Pillai
• Padmakumar Karunakaran Pillai
• Sajitha Pillai
• Rajitha Gopalakrishnan
• Aditya Arun Kumar
• Hemalatha Pillai

Company Capital Structure

Onesource Specialty Pharma Limited maintains a stable equity share capital structure. The company's total equity share capital remains unchanged at 11,46,21,201 equity shares of Rs. 1 each, fully paid up. The shares are listed on both BSE Limited (Scrip Code: 544292) and National Stock Exchange of India Limited (Scrip Code: ONESOURCE).

Regulatory Compliance

The disclosure was signed by Jyothinarayasha Sriraman Ramaprasad, Designated Partner of Pronomz Ventures LLP (DIN: 00173696), on February 02, 2026. The filing ensures compliance with SEBI regulations governing substantial acquisitions and maintains transparency in shareholding changes for publicly listed companies.

OneSource Specialty Pharma Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing mixed performance amid operational challenges. The pharmaceutical contract development and manufacturing organization (CDMO) reported its Q3 FY26 results following board approval on January 23, 2026.

Consolidated Financial Performance

The company's consolidated operations reflected challenging market conditions during the quarter. Revenue from operations declined to ₹2,903.40 million in Q3 FY26 compared to ₹3,925.63 million in Q3 FY25.

For the nine-month period ended December 31, 2025, consolidated revenue from operations reached ₹9,933.73 million compared to ₹10,189.00 million in the corresponding period of FY25, indicating a decline of 2.51%.

Standalone Results Analysis

On a standalone basis, the company reported revenue from operations of ₹2,902.20 million for Q3 FY26, down from ₹3,367.49 million in Q3 FY25. The standalone net loss widened to ₹621.85 million compared to ₹730.23 million loss in the previous year's quarter.

Exceptional Items and Operational Costs

The company recorded exceptional items totaling ₹70.90 million during Q3 FY26, comprising employee one-time mutual separation settlement of ₹41.47 million and gratuity and compensated absences impact under new labor codes of ₹29.43 million. This compares to exceptional items of ₹1,005.23 million in Q3 FY25, which primarily included business combination and listing-related expenses.

Total consolidated expenses for the quarter amounted to ₹3,808.86 million, with significant components including:

• Employee benefits expenses: ₹641.92 million
• Depreciation and amortization: ₹696.37 million
• Finance costs: ₹382.31 million
• Other expenses: ₹1,144.60 million

Corporate Developments

The company has entered into a Composite Scheme of Arrangement and Amalgamation involving multiple entities including Brooks Steriscience Limited, Steriscience Pte Limited, and Strides Pharma Services Private Limited. The scheme, approved by the Board of Directors on September 26, 2025, is currently awaiting regulatory approvals.

Additionally, on December 22, 2025, the company approved an amalgamation of its wholly-owned subsidiaries Stelis Pte. Ltd. and OneSource Specialty Pte. Ltd. under Singapore's Companies Act. The amalgamation received regulatory approval on January 14, 2026, and became effective from January 1, 2026.

Segment Performance

The company operates primarily in the CDMO segment, which reported revenue of ₹2,903.40 million for Q3 FY26 compared to ₹3,925.63 million in Q3 FY25. The segment recorded a loss before tax of ₹930.11 million during the quarter, compared to a loss of ₹665.02 million in the corresponding previous quarter.